Five Under 5: Top Oncology Videos for the Week of 10/25 - ESMO 2026 Edition

Welcome to The Five Under 5, your go-to roundup of the top 5 videos of the week.

These short videos are designed for busy oncologists to view on the go, and feature expert insights on breaking news, regulatory updates, practice-changing data shared at medical meetings, and other key topics in the realm of oncology.

This week, we’re highlighting exclusive interviews conducted during the 2026 ESMO Congress. Here’s what you may have missed:

Interim Overall Survival Data From DUO-E in Advanced or Recurrent Endometrial Cancer: Shannon N. Westin, MD, MPH, FACOG

Shannon N. Westin, MD, MPH, FACOG, of The University of Texas MD Anderson Cancer Center, reviewed interim overall survival (OS) data from the phase 3 DUO-E trial (NCT04269200), which were presented at the 2026 ESMO Congress. The trial evaluated durvalumab (Imfinzi) plus carboplatin and paclitaxel followed by maintenance durvalumab with or without olaparib (Lynparza) in patients with advanced or recurrent endometrial cancer, and it previously met its dual primary end points of progression-free survival (PFS) in the intention-to-treat population. At 52.1% maturity, durvalumab reduced the risk of death by 13% and durvalumab plus olaparib reduced it by 23% vs control, with the combination translating to an 11.5-month OS gain; however, these improvements did not reach statistical significance. In the exploratory mismatch repair–deficient subgroup, the combination reduced the risk of death by 57% vs 43% with durvalumab alone, and in the mismatch repair–proficient subgroup, adding olaparib yielded a 15% risk reduction and an 8-month OS gain. Westin noted that the final OS analysis was expected at approximately 60% maturity within the next year.

Interim Safety Data for Lutetium Lu 177 Vipivotide Tetraxetan Retreatment in mCRPC: Johanna Enke, MD

Johanna Enke, MD, of UCLA Health, detailed interim safety data from the phase 2 Re-LuPSMA trial (NCT06288113) of lutetium Lu 177 vipivotide tetraxetan (Pluvicto) retreatment in patients with metastatic castration-resistant prostate cancer who had previously responded to the agent. Eligible patients had received 4 to 6 prior cycles, achieved a prostate-specific antigen decline of at least 50%, and subsequently experienced disease progression. Of 20 enrolled patients, 19 received at least 1 retreatment dose, with a median time from prior therapy to retreatment of 9.2 months and a median of 3 retreatment cycles. Of 165 reported adverse effects (AEs), 88 were possibly treatment related, most commonly lymphocytopenia, leukopenia, and anemia. The predefined stopping threshold of 5 treatment-related serious AEs was not reached, although 2 cases of serious anemia required hospitalization.

Ixotatug Vedotin in Heavily Pretreated Recurrent Germ Cell Tumors: Darren R. Feldman, MD

Darren R. Feldman, MD, of Memorial Sloan Kettering Cancer Center, highlighted data from the phase 1 CATALINA-1 trial (NCT05103683) of ixotatug vedotin (TORL-1-23), a claudin 6–directed antibody-drug conjugate, in patients with heavily pretreated recurrent germ cell tumors. Among the 11 patients in the cohort, 9 had received at least 3 prior lines of chemotherapy and 6 had undergone prior high-dose chemotherapy with autologous stem cell transplant. The objective response rate (ORR) was 45.5% (95% CI, 16.7-76.6), all 5 responses were partial, and the disease control rate was 72.7%. At a median follow-up of 13.8 months, the median PFS was 5.8 months (95% CI, 1.4-13.8), and 3 of the 6 patients with prior transplant responded. One patient remained in response at the March 2026 data cutoff, nearly 4 years after starting treatment, although Feldman noted that duration-of-response data were still immature.

INTerpath-001 Data for Intismeran Autogene Plus Pembrolizumab in Resected Melanoma: Georgina V. Long, AO, BSc, PhD, MBBS

Georgina V. Long, AO, BSc, PhD, MBBS, of Melanoma Institute Australia, presented findings from the phase 3 INTerpath-001 trial (NCT05933577) of adjuvant intismeran autogene (mRNA-4157; V940) plus pembrolizumab (Keytruda) in patients with resected stage IIB to IV melanoma. Overall, 1137 patients were randomly assigned 2:1 to receive intismeran plus pembrolizumab (n = 757) or placebo plus pembrolizumab (n = 380). At a median follow-up of 24.6 months, the combination reduced the risk of recurrence or death by 42% (HR, 0.58; 95% CI, 0.45-0.75; P < .001), with 24-month recurrence-free survival rates of 82.2% vs 70.0%, respectively. The combination also reduced the risk of distant metastasis or death by 38% (HR, 0.62; 95% CI, 0.45-0.85; P = .002). Intismeran did not increase immune-related AEs associated with pembrolizumab, and its toxicities were limited to transient grade 1 or 2 injection-site and vaccination-related reactions.

First-Line Amivantamab Plus Pembrolizumab and Carboplatin in HNSCC: Paul L. Swiecicki, MD

Paul L. Swiecicki, MD, of the University of Michigan Rogel Cancer Center, outlined results from cohort 5 of the phase 1b/2 OrigAMI-4 trial (NCT06385080) evaluating subcutaneous amivantamab and hyaluronidase-lpuj (Rybrevant Faspro) plus pembrolizumab and carboplatin as first-line therapy for patients with recurrent/metastatic head and neck squamous cell carcinoma. Eligible patients had not received prior PD-1/PD-L1 or EGFR inhibitors and had a PD-L1 combined positive score of at least 1. Among patients with human papillomavirus (HPV)–unrelated disease (n = 22), the confirmed ORR was 77% (95% CI, 55-92), including a complete response rate of 14%. At a median follow-up of 10.6 months, the median OS was not reached, and 77% of patients were alive at 1 year. Swiecicki noted that the phase 3 OrigAMI-5 trial (NCT07276399) was comparing subcutaneous amivantamab plus pembrolizumab and carboplatin vs carboplatin, 5-fluorouracil, and pembrolizumab in patients with HPV-unrelated disease regardless of PD-L1 status.